Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Current and Future Perspectives of Theranostics in the Field of NETs

New E-Learning module by Philippe Ruszniewski, Rachida Lebtahi and Louis de Mestier is now available. Watch the presentation and take the CME test today!

E-learning video block

This content is for ESMO members only.



Download slides

Learning objectives

  1. To provide principles of the use of theranostics in neuroendocrine tumours
  2. To provide current applications of theranostics in neuroendocrine tumours
  3. To provide perspectives of theranostics in neuroendocrine tumours


In this E-Learning module, the authors elaborate essentials in neuroendocrine tumours (NET’s). They provide basic principles of the theranostics use in NETs, describe the current applications of theranostics in NETs, provide an overview of modern pivotal phase III clinical trials in patients with advanced NETs, algorithms for the management based on the clinical practice guidelines and elaborate theranostics perspective in NETs.  

NETs are rare neoplasms with increasing incidence. Most NETs arise from the digestive and pulmonary systems. Most NETs are associated with metastases. Patients with metastatic NETs often have prolonged course of disease with 5-year overall survival rate of 50-70%. The main prognostic factors of NETs are the primary tumour site, stage, grade (Ki-67), tumour growth rate and tumour burden.

Therapeutic options for non-resectable NETs include long-acting somatostatin analogues (lanreotide, octreotide), systemic chemotherapy (alkylating agents, platinum-based), transarterial (chemo)-embolisation, everolimus, sunitinib, peptide receptor-radionuclide therapy (177Lu-DOTATATE). Therapeutic decision making mostly relies on prognostic factors. The authors underline that these treatments have not or poorly been compared between each other, factors predictive of their efficacy have yet to be determined and emphasise on the importance of multidisciplinary expert discussions.

In this interesting module, the authors provide the theranostics definition as the use of a diagnostic test, identifying a marker, to guide the patient's therapy according to the marker status. Mechanisms of action of radiopharmaceuticals are elaborated and current applications well explained, clinical benefits and toxicities described, the results from the clinical studies detailed, and future perspectives elaborated as emerging pharmaceuticals should be explored.

Declaration of interest

Philippe Ruszniewski has reported:
Financial Interests:
Invited Speaker, Personal: Ipsen.
Invited Speaker, Personal, Advisory Board, Personal, Funding, Institutional: AAA.

Louis de Mestier du Bourg has reported:
Financial Interests:
Invited Speaker, Personal: AAA, Keocyt.
Advisory Board, Personal: Ipsen, Sirtex, Pfizer, Novartis.

Rachida Lebtahi has reported:
Financial Interests:
Advisory Board, Personal: AAA Novartis, Sirtex.

Last update: 26 Oct 2021

This E-learning module was published in 2021. The CME test expired in 2024.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.